AR072470A1 - Moduladores de los canales de iones de calcio y sus usos - Google Patents

Moduladores de los canales de iones de calcio y sus usos

Info

Publication number
AR072470A1
AR072470A1 ARP090102503A ARP090102503A AR072470A1 AR 072470 A1 AR072470 A1 AR 072470A1 AR P090102503 A ARP090102503 A AR P090102503A AR P090102503 A ARP090102503 A AR P090102503A AR 072470 A1 AR072470 A1 AR 072470A1
Authority
AR
Argentina
Prior art keywords
group
groups
hydrogen atom
unsubstituted
alkyl
Prior art date
Application number
ARP090102503A
Other languages
English (en)
Original Assignee
Lectus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lectus Therapeutics Ltd filed Critical Lectus Therapeutics Ltd
Publication of AR072470A1 publication Critical patent/AR072470A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

Son bloqueadores de los canales Cavx y son utiles en el tratamiento de diversas afecciones incluyendo el dolor. Composiciones farmacéuticas. Reivindicacion 1: Un compuesto representado mediante la formula general (1) o su sal o profármaco aceptable para uso farmacologico, donde R1, R2, R3 y R4 se seleccionan independientemente entre átomos de hidrogeno, grupos alquilo, hidroxialquilo, átomos de halogeno, grupos haloalquilo, alcoxi, haloalcoxi, alcoxicarbonilo, carboxilo, hidroxilo, nitro, amino, monoalquilamino, dialquilamino, acilamino, alcoxicarbonilamino, alquilsulfonilo, arilsulfonilo, alquilsulfonilamino, arilsulfonilamino, aminosulfonilo y grupos ciano, o cualesquiera dos de R1 a R4 que están adyacentes en el anillo pueden en forma conjunta representar la porcion -O-(CH2)n-O- donde n es un numero entero entre 1 y 3; R5 es un átomo de hidrogeno o un grupo alquilo; R6 es un átomo de hidrogeno o un grupo alquilo; y X se selecciona del grupo formado por: (a) grupos de formula OR7 donde R7 es un átomo de hidrogeno o un grupo alquilo el cual está opcionalmente sustituido con un sustituyente seleccionado del grupo formado por grupos alquilsulfonilalquilo, grupos heterocíclicos saturados o parcialmente insaturados, grupos alcoxi, grupos carboxilo, nitro, amino, monoalquilamino, dialquilamino, átomos de halogeno, y grupos alcoxicarbonilo, siempre y cuando R7 es H o etilo, entonces R1, R2, R3 y R4 no pueden seleccionarse entra átomos de hidrogeno, átomos de halogeno y grupos alquilo; y (b) grupos de formula NR8R9 donde R8 y R9 junto con el átomo de nitrogeno al cual están unidos forman un grupo heterocíclico saturado o parcialmente insaturado el cual opcionalmente contiene por lo menos un heteroátomo más seleccionado entre átomos de nitrogeno, oxigeno y azufre, dicho grupo heterocíclico saturado o parcialmente insaturado es además opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo formado por grupos alquilo, átomos de halogeno, grupos haloalquilo, alcoxi, alcoxicarbonilo, carboxilo, nitro, amino, monoalquilamino, dialquilamino y grupo hidroxilo, siempre que: (i) cuando R8 y R9 junto con el átomo de nitrogeno al cual están unidos forman un grupo piperazina, y uno o más de R1 a R4 se seleccionan entre átomos de hidrogeno, grupos hidroxilo, nitro, amino, alquilamino, dialquilamino, alcoxicarbonilamino, átomos de halogeno, grupos alcoxi y grupos alquilo, el átomo de nitrogeno del grupo piperazina en la posicion 4 del anillo no puede ser sustituido con un grupo alquilo, (ii) cuando cada uno de R1, R2, R3, R4, R5 y R6 es un átomo de hidrogeno, entonces X no puede ser un grupo piperazinilo no sustituido o un grupo morfolino no sustituido, (iii) cuando cada uno de R1, R2, R4, R5 y R6 es un átomo de hidrogeno y R3 se selecciona del grupo formado por un átomo de hidrogeno, un átomo de bromo y un grupo hidroxilo, entonces X no puede ser un grupo metoxi, (iv) cuando cada uno de R2 y R3 es un grupo metoxi o representan en forma conjunta la porcion -O-CH2-O- y cada uno de R1, R4, R5 y R6 es un átomo de hidrogeno, entonces X no puede ser un grupo piperidina no sustituido, un grupo morfolino no sustituido, un grupo pirrolidina no sustituido, un grupo azepano no sustituido, un grupo azocano no sustituido, o cuando R2 y R3 en forma conjunta representan la porcion -O-CH2-O- y cada uno de R1, R4, R5 y R6 es un átomo de hidrogeno X no puede representar un grupo 4-metilpiperazina.
ARP090102503A 2008-07-03 2009-07-03 Moduladores de los canales de iones de calcio y sus usos AR072470A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0812192.3A GB0812192D0 (en) 2008-07-03 2008-07-03 Calcium ion channel modulators & uses thereof

Publications (1)

Publication Number Publication Date
AR072470A1 true AR072470A1 (es) 2010-09-01

Family

ID=39717915

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102503A AR072470A1 (es) 2008-07-03 2009-07-03 Moduladores de los canales de iones de calcio y sus usos

Country Status (20)

Country Link
US (1) US20110166136A1 (es)
EP (1) EP2303840A2 (es)
JP (1) JP2011526618A (es)
KR (1) KR20110046460A (es)
CN (1) CN102143946A (es)
AR (1) AR072470A1 (es)
AU (1) AU2009265292A1 (es)
BR (1) BRPI0913970A2 (es)
CA (1) CA2729688A1 (es)
CO (1) CO6341611A2 (es)
EA (1) EA201170135A1 (es)
GB (1) GB0812192D0 (es)
IL (1) IL210224A0 (es)
MA (1) MA32429B1 (es)
MX (1) MX2010014455A (es)
PE (1) PE20110406A1 (es)
TW (1) TW201004942A (es)
UY (1) UY31959A (es)
WO (1) WO2010001179A2 (es)
ZA (1) ZA201100068B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105481851A (zh) * 2014-09-19 2016-04-13 龚兆龙 六氢苯并萘啶类光学活性化合物及其药物用途
WO2018100206A1 (en) * 2016-12-02 2018-06-07 Sophion Bioscience A/S Seal enhancer
US11215606B2 (en) 2016-12-02 2022-01-04 Sophion Bioscience A/S Seal enhancer
CN115894330A (zh) * 2022-09-06 2023-04-04 吉林医药学院 一种1-乙酰基-1h-吲哚-3-基乙酸酯衍生物的合成方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825734A (en) * 1955-04-11 1958-03-04 Upjohn Co Reduction of carbonylic radicals in indolyl-3 compounds
GB944443A (es) * 1959-09-25 1900-01-01
US3217011A (en) * 1965-05-07 1965-11-09 Sterling Drug Inc 1-(indolyglyoxalyl)-piperidines
GB9523999D0 (en) * 1995-11-23 1996-01-24 Lilly Co Eli Indolyl neuropeptide y receptor antagonists
US5756507A (en) * 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19946301A1 (de) * 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
JP2006510673A (ja) * 2002-12-10 2006-03-30 ワイス プラスミノゲンアクティベータインヒビター１（ｐａｉ−１）のインヒビターとしての、アリール、アリールオキシ、および、アルキルオキシ置換１ｈ−インドール−３−イルグリオキシル酸誘導体
UA80453C2 (en) * 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
ES2325071T3 (es) * 2002-12-10 2009-08-25 Wyeth Derivados del acido indol-oxo-acetilaminoacetico sustituido como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1).
WO2007040166A1 (ja) * 2005-09-30 2007-04-12 Dainippon Sumitomo Pharma Co., Ltd. 新規な縮合ピロール誘導体
RU2008118001A (ru) * 2005-10-06 2009-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы атф-зависимых транспортеров
AU2007217363A1 (en) * 2006-02-27 2007-08-30 Wyeth Inhibitors of PAI-1 for treatment of muscular conditions
US7504399B2 (en) * 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents

Also Published As

Publication number Publication date
EP2303840A2 (en) 2011-04-06
EA201170135A1 (ru) 2011-10-31
JP2011526618A (ja) 2011-10-13
IL210224A0 (en) 2011-03-31
CO6341611A2 (es) 2011-11-21
AU2009265292A1 (en) 2010-01-07
GB0812192D0 (en) 2008-08-13
CA2729688A1 (en) 2010-01-07
MX2010014455A (es) 2011-04-11
KR20110046460A (ko) 2011-05-04
BRPI0913970A2 (pt) 2018-05-29
CN102143946A (zh) 2011-08-03
US20110166136A1 (en) 2011-07-07
PE20110406A1 (es) 2011-06-19
WO2010001179A2 (en) 2010-01-07
WO2010001179A3 (en) 2010-11-11
MA32429B1 (fr) 2011-06-01
TW201004942A (en) 2010-02-01
UY31959A (es) 2010-01-05
ZA201100068B (en) 2012-06-27

Similar Documents

Publication Publication Date Title
ES2509820T3 (es) Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer
AR043111A1 (es) Derivados monoacilados de o-fenilendiaminas
AR025975A1 (es) Compuestos quimicos.
AR054365A1 (es) Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos.
AR069435A1 (es) Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa
AR057989A1 (es) Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas
AR074596A1 (es) Derivados de (3-oxo) piridazin-4-ilurea
CO5700754A2 (es) Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR048652A1 (es) 4-fenilamino-quinazolin-6-il-amidas
AR033295A1 (es) Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
CO5060482A1 (es) Derivados terapeuticos de biarilo
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR023754A1 (es) Benzimidazoles sustituidos por cicloalquilo, su obtencion y uso
CO5721001A2 (es) Derivados sustituidos de morfolina y tiomorfolina
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR070992A1 (es) Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1
AR077440A1 (es) Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas
CO5720994A2 (es) Derivados sustituidos del pirrol
CO6160307A2 (es) Compuestos de pirazolina y su uso y composiciones farmaceuticas
RS52562B (en) (3-ARIL-PIPERAZINE-1-IL) DERIVATI 6,7-DIALCOKSIQUINZOLINE, 6,7-DIALCOKSIFTALAZINE I
CO5700763A2 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra

Legal Events

Date Code Title Description
FB Suspension of granting procedure